Keyphrases
Diabetic Keratopathy
100%
Naltrexone
100%
Novel Treatments
100%
Specific Intent
83%
Type 1 Diabetes Mellitus (T1DM)
50%
Type I Diabetes
50%
Corneal Epithelium
50%
Corneal Re-epithelialization
33%
Diabetic Patients
33%
Corneal Wound Healing
33%
Corneal Abrasion
16%
Ophthalmologist
16%
Full-thickness
16%
Scar
16%
Naltrexone Treatment
16%
Donor Cornea
16%
Topical Application
16%
Reliable Model
16%
Receptor-ligand Interaction
16%
Innovative Approach
16%
Therapeutic Potential
16%
Molecular Biology
16%
Corneal Epithelial
16%
Phase I Clinical Trial
16%
Wound Complications
16%
Opioid Antagonist
16%
Diabetic
16%
Opioid Receptors
16%
Due Diligence
16%
Regulatory Mechanism
16%
Interdisciplinary Research Teams
16%
Diabetes
16%
Recurrent Erosions
16%
Bench to Bedside
16%
Vitrectomy
16%
Clinical Trials
16%
Two-species
16%
Subcutaneous Insulin
16%
Vision Loss
16%
Biostatistician
16%
Cell Biology
16%
Subepithelial Lesion
16%
Toxic Dose
16%
Growth Regulators
16%
Animal Experiment
16%
Basic Scientist
16%
Institutional Review Board
16%
Biotherapy
16%
Streptozotocin-induced Diabetic Rats
16%
Medicine and Dentistry
Bullous Keratopathy
100%
Naltrexone
100%
Diabetes Mellitus
57%
Insulin Dependent Diabetes Mellitus
42%
Corneal Epithelium
42%
Diabetes
28%
Wound Healing
28%
Clinical Trial
28%
Epithelization
28%
Skin Defect
14%
Opiate Antagonist
14%
Persistent Corneal Epithelial Defect
14%
Scar Formation
14%
Streptozocin
14%
Topical Drug Administration
14%
Vitrectomy
14%
Biological Therapy
14%
Corneal Abrasion
14%
Corneal Ulcer
14%
Alloxan
14%
Pharmacology, Toxicology and Pharmaceutical Science
Keratopathy
100%
Naltrexone
100%
Leporidae
71%
Diabetes Mellitus
57%
Insulin Dependent Diabetes Mellitus
42%
Skin Defect
28%
Clinical Trial
28%
Wound Healing
28%
Cornea Ulcer
14%
Cornea Erosion
14%
Alloxan
14%
Opiate Receptor
14%
Scar Formation
14%
Streptozotocin
14%